Topical vs. Oral Period Pain Relief: Why Care At The Source Matters

When period cramps hit, the routine is familiar: you reach for ibuprofen, wait 45 minutes, and hope for the best. Sometimes it takes the edge off, sometimes it doesn’t. 

Either way, you've just sent a systemic drug on a tour of your entire body to get to one very specific destination: your uterus. That's a surprisingly roundabout solution for a pain problem that's highly localized. 

The standard playbook for period pain hasn't changed much in decades: take an oral NSAID (that's a nonsteroidal anti-inflammatory drug), and repeat as needed. It works for a lot of people, but if you've ever felt like your go-to painkillers are doing less than they should, you're asking the right question.

Luckily, the science of period pain relief is catching up. Here's what's actually happening when you take oral pain medication for cramps: where it works, where it falls short, and why localized, topical period pain relief is emerging as a smarter approach for many women.

How oral pain medication works 

When you swallow oral over-the-counter pain relief (like Tylenol, Advil, or Aleve), it doesn't go straight to your uterus. It travels through your digestive system, gets absorbed into your bloodstream, circulates through your entire body, and eventually reaches the site of pain (your uterus) at whatever concentration is left. Standard oral ibuprofen tablets typically take one to two hours to reach peak plasma levels after ingestion. That's a long time to wait when cramps are already in full swing.

NSAIDs work by blocking cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for producing prostaglandins, the compounds that trigger uterine contractions and, by extension, period pain. And they do work: a large Cochrane review of 80 randomized controlled trials confirmed that NSAIDs significantly outperform placebo for period pain relief. For many women, ibuprofen or naproxen taken at the right dose, at the right time, does the job.

But not for everyone. Some estimates suggest that around 18%-20% of women don't respond adequately to NSAIDs for period pain, meaning they get insufficient relief, can't tolerate the side effects, or both. The science on why NSAID resistance happens is still evolving, but for a meaningful proportion of women, the answer isn't simply taking more pills.

Then there's the side effect question, which is relevant even for women who do get relief. Because NSAIDs suppress prostaglandin production throughout the entire body (not just in the uterus), that whole-body exposure comes with trade-offs: gastrointestinal irritation, nausea, headaches, and, with prolonged use, potential cardiovascular concerns. Taken occasionally, these side effects aren't anything to worry about. But for anyone managing cramps every single cycle, that's a cumulative burden worth taking seriously.

The case for localized, topical period pain relief

The logic of localized care is straightforward: if the pain is coming from your uterus, delivering relief as close to the source as possible — and bypassing the long systemic journey — makes physiological sense.

This is why topical and intravaginal drug delivery has become an active area of research for period pain. Rather than routing a drug through the digestive tract and bloodstream before it reaches the uterus, a localized formulation can act directly at the target tissue, at higher local concentrations and with less systemic exposure. Think of it as precision over breadth. You're not asking your whole body to absorb a drug in the hope that enough of it reaches your uterus; you're delivering it exactly where it needs to go.

This idea isn't completely new. Diclofenac, a type of anti-inflammatory medicine, has been studied for years as a suppository. This method can deliver the medicine directly with fewer stomach issues. What is new is the research around cannabinoids and how they interact with uterine tissue in special ways.

The uterus and the endocannabinoid system

The endocannabinoid system (ECS) is a network in the body that helps control pain, inflammation, and muscle tone. It works through two main types of receptors called CB1 and CB2, which are found in many body tissues, including the uterus. Research shows that there are many cannabinoid receptors in the smooth muscle of the human uterus. Studies suggest that cannabinoids can directly relax the contractions of uterine muscle cells in lab tests.

This matters because period pain — specifically primary dysmenorrhea, which is cramp pain with no underlying condition behind it — is fundamentally a muscle problem. The uterus contracts to shed its lining each month, and in some women, those contractions are intense enough to restrict blood flow and cause significant pain. The ECS appears to play a role in regulating those contractions, with CB1 receptor activation linked to reduced uterine muscle activity. In plain terms, cannabinoids may be able to dial down cramping through a completely different pathway to NSAIDs, which means the two approaches could work well together rather than simply duplicating each other.

Early lab studies have also shown that both CBD and CBDA can relax pre-tensed uterine muscle tissue, a finding that helped inform the development of intravaginal CBD formulations for period pain.

What the clinical evidence shows

Vella's Ebbtide was built on this science. It's a vaginal insert that delivers CBD and CBDA directly to the tissue closest to the uterus, so the active ingredients get to where the pain is without making a round trip through the rest of your body first.

In a clinical trial of 48 women with period pain, using Ebbtide daily during their period led to a significant reduction in pain — 44% on average, and up to 68% in women who started with moderate cramps. But perhaps the most telling result: 81% of participants said they needed less oral pain medication while using it, and more than half said they'd swap pills for Ebbtide entirely. For anyone who's been reaching for ibuprofen every cycle, that's a real change.

It was also well-tolerated. Three-quarters of participants experienced no discomfort at all, and any minor side effects resolved on their own.

Oral or topical: Does it have to be either/or?

For many people, combining approaches makes the most sense. Using a localized formulation to address cramping at the source, with oral medication as a backup for days when pain is more widespread or severe. In the clinical trial, over 70% of participants said they would use Ebbtide alongside pain medication when needed. That flexibility is part of the point.

Part of why we're only now asking these questions is a story in itself. Pain has always been notoriously difficult to study because it's hard to measure objectively. But research has also consistently shown that women's pain is taken less seriously than men's: a 2024 study published in PNAS found that female patients in emergency departments waited longer to be seen and were less likely to be prescribed pain relief for the same complaints. 

When the pain in question is menstrual, the problem compounds. Women are often socialized from a young age to believe that painful periods are just part of being a woman, something to be managed and pushed through rather than investigated and treated. That cultural narrative has real consequences because it shapes what gets researched, what gets funded, and what options get developed.

The science is starting to catch up. And what it's making clear is that oral medication shouldn't be the default just because it's always been the default. Period pain is a localized problem. The tools we use to address it should be able to meet it there — precisely, and without asking the rest of your body to bear the burden.